Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Cemiplimab

Future steps following a Phase II trial of cemiplimab in BCCHN
0:33
Future steps following a Phase II trial of cemiplimab in BCCHN
Hannah Kenny • 17 Jun 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 17 Jun 2026
How will adjuvant cemiplimab improve outcomes in high risk CSCC?
0:40
How will adjuvant cemiplimab improve outcomes in high risk CSCC?
Danny Rischin • 11 Jun 2026
Adjuvant cemiplimab in high-risk CSCC: DFS subanalyses from the C-POST trial
1:12
Adjuvant cemiplimab in high-risk CSCC: DFS subanalyses from the C-POST trial
Danny Rischin • 11 Jun 2026
Can immunotherapy reduce surgery in advanced head & neck BCC?
0:48
Can immunotherapy reduce surgery in advanced head & neck BCC?
Joseph Curry • 10 Jun 2026
Cytokine dynamics and metronomic chemo-immunotherapy in R/M HNSCC
1:27
Cytokine dynamics and metronomic chemo-immunotherapy in R/M HNSCC
Marcelo Bonomi • 10 Jun 2026
Neoadjuvant cemiplimab in HHI-naive head & neck basal cell carcinoma
1:21
Neoadjuvant cemiplimab in HHI-naive head & neck basal cell carcinoma
Hannah Kenny • 31 May 2026
Circulating HPV DNA in surveillance and MRD-guided head & neck cancer care
1:35
Circulating HPV DNA in surveillance and MRD-guided head & neck cancer care
Ari Rosenberg • 6 May 2026
Assessing the role of metronomic regimens in head and neck cancers
0:53
Assessing the role of metronomic regimens in head and neck cancers
Marcelo Bonomi • 17 Nov 2025
Metronomic chemotherapy and cemiplimab in recurrent/metastatic HNSCC
0:54
Metronomic chemotherapy and cemiplimab in recurrent/metastatic HNSCC
Marcelo Bonomi • 17 Nov 2025
Phase II trial of BNT111 and cemiplimab in PD-1–refractory melanoma
2:31
Phase II trial of BNT111 and cemiplimab in PD-1–refractory melanoma
Paolo Ascierto • 11 Nov 2025
Which patients with NSCLC will potentially benefit from cemiplimab?
0:41
Which patients with NSCLC will potentially benefit from cemiplimab?
Ana Baramidze • 12 Sep 2025
Investigating the role of cemiplimab in non-small cell lung cancer
0:55
Investigating the role of cemiplimab in non-small cell lung cancer
Ana Baramidze • 12 Sep 2025
EMPOWER-Lung 3: 5-year results of cemiplimab & chemotherapy in NSCLC
1:40
EMPOWER-Lung 3: 5-year results of cemiplimab & chemotherapy in NSCLC
Ana Baramidze • 9 Sep 2025
Evaluating fianlimab and cemiplimab in PD-L1+ recurrent/metastatic HNSCC
1:04
Evaluating fianlimab and cemiplimab in PD-L1+ recurrent/metastatic HNSCC
Danny Rischin • 2 Jun 2025
C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma
1:45
C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma
Danny Rischin • 2 Jun 2025
The content of VJOncology is intended for healthcare professionals